Timothy Winton

Summary

Affiliation: University of Alberta
Country: Canada

Publications

  1. ncbi request reprint Vinorelbine plus cisplatin vs. observation in resected non-small-cell lung cancer
    Timothy Winton
    National Cancer Institute of Canada Clinical Trials Group, Kingston, Ont
    N Engl J Med 352:2589-97. 2005
  2. pmc Quality-of-life outcomes for adjuvant chemotherapy in early-stage non-small-cell lung cancer: results from a randomized trial, JBR.10
    Andrea Bezjak
    National Cancer Institute of Canada Clinical Trials Group, Cancer Centre of Southeastern Ontario, Kingston, ON, Canada
    J Clin Oncol 26:5052-9. 2008
  3. ncbi request reprint Compliance with post-operative adjuvant chemotherapy in non-small cell lung cancer. An analysis of National Cancer Institute of Canada and intergroup trial JBR.10 and a review of the literature
    Naveed Alam
    National Cancer Institute of Canada Clinical Trials Group, 10 Stuart Street, Kingston, Ont, Canada K7L3N6
    Lung Cancer 47:385-94. 2005
  4. doi request reprint Pooled analysis of the effect of age on adjuvant cisplatin-based chemotherapy for completely resected non-small-cell lung cancer
    Martin Fruh
    Department of Medical Oncology, Princess Margaret Hospital, Toronto
    J Clin Oncol 26:3573-81. 2008
  5. doi request reprint Lung adjuvant cisplatin evaluation: a pooled analysis by the LACE Collaborative Group
    Jean Pierre Pignon
    Institut Gustave Roussy, 39 rue Camille Desmoulins, 94805 Villejuif, France
    J Clin Oncol 26:3552-9. 2008
  6. ncbi request reprint Class III beta-tubulin expression and benefit from adjuvant cisplatin/vinorelbine chemotherapy in operable non-small cell lung cancer: analysis of NCIC JBR.10
    Pascal Seve
    Cross Cancer Institute, University of Alberta, Edmonton, Alberta, Canada
    Clin Cancer Res 13:994-9. 2007
  7. ncbi request reprint Induction chemoradiation and surgical resection for superior sulcus non-small-cell lung carcinomas: long-term results of Southwest Oncology Group Trial 9416 (Intergroup Trial 0160)
    Valerie W Rusch
    Thoracic Surgery Service, Memorial Sloan Kettering Cancer Center, New York, NY, USA
    J Clin Oncol 25:313-8. 2007
  8. ncbi request reprint Validating the prognostic value of marker genes derived from a non-small cell lung cancer microarray study
    Fiona H Blackhall
    Division of Cellular and Molecular Biology, University Health Network, Ontario Cancer Institute, Princess Margaret Hospital and University of Toronto, Toronto, Ontario, Canada M5G 2M9
    Lung Cancer 46:197-204. 2004
  9. ncbi request reprint Skp2 gene copy number aberrations are common in non-small cell lung carcinoma, and its overexpression in tumors with ras mutation is a poor prognostic marker
    Chang Qi Zhu
    University Health Network, Ontario Cancer Institute and Princess Margaret Hospital, University of Toronto, Toronto, Ontario, Canada
    Clin Cancer Res 10:1984-91. 2004
  10. ncbi request reprint Molecular profiling of non-small cell lung cancer and correlation with disease-free survival
    Dennis A Wigle
    Thoracic Oncology Site Group, Princess Margaret Hospital, Samuel Lunenfeld Research Institute of Mount Sinai Hospital, University of Toronto, 610 University Avenue, Toronto, Ontario, Canada M5G 2M9
    Cancer Res 62:3005-8. 2002

Collaborators

Detail Information

Publications11

  1. ncbi request reprint Vinorelbine plus cisplatin vs. observation in resected non-small-cell lung cancer
    Timothy Winton
    National Cancer Institute of Canada Clinical Trials Group, Kingston, Ont
    N Engl J Med 352:2589-97. 2005
    ..We undertook to determine whether adjuvant vinorelbine plus cisplatin prolongs overall survival among patients with completely resected early-stage non-small-cell lung cancer...
  2. pmc Quality-of-life outcomes for adjuvant chemotherapy in early-stage non-small-cell lung cancer: results from a randomized trial, JBR.10
    Andrea Bezjak
    National Cancer Institute of Canada Clinical Trials Group, Cancer Centre of Southeastern Ontario, Kingston, ON, Canada
    J Clin Oncol 26:5052-9. 2008
    ..We report the QOL results of JBR.10, a North American, intergroup, randomized trial of adjuvant cisplatin and vinorelbine compared with observation in patients who have completely resected, stages IB to II NSCLC...
  3. ncbi request reprint Compliance with post-operative adjuvant chemotherapy in non-small cell lung cancer. An analysis of National Cancer Institute of Canada and intergroup trial JBR.10 and a review of the literature
    Naveed Alam
    National Cancer Institute of Canada Clinical Trials Group, 10 Stuart Street, Kingston, Ont, Canada K7L3N6
    Lung Cancer 47:385-94. 2005
    ..Differences between nations in the perception of the risks and benefits of adjuvant chemotherapy regimens, both between physicians and patients, should be investigated further...
  4. doi request reprint Pooled analysis of the effect of age on adjuvant cisplatin-based chemotherapy for completely resected non-small-cell lung cancer
    Martin Fruh
    Department of Medical Oncology, Princess Margaret Hospital, Toronto
    J Clin Oncol 26:3573-81. 2008
    ..This pooled analysis was undertaken to assess the efficacy and toxicity of adjuvant cisplatin-based chemotherapy in elderly patients with non-small-cell lung cancer (NSCLC)...
  5. doi request reprint Lung adjuvant cisplatin evaluation: a pooled analysis by the LACE Collaborative Group
    Jean Pierre Pignon
    Institut Gustave Roussy, 39 rue Camille Desmoulins, 94805 Villejuif, France
    J Clin Oncol 26:3552-9. 2008
    ..The aim of the Lung Adjuvant Cisplatin Evaluation was to identify treatment options associated with a higher benefit or groups of patients who particularly benefit from postoperative chemotherapy...
  6. ncbi request reprint Class III beta-tubulin expression and benefit from adjuvant cisplatin/vinorelbine chemotherapy in operable non-small cell lung cancer: analysis of NCIC JBR.10
    Pascal Seve
    Cross Cancer Institute, University of Alberta, Edmonton, Alberta, Canada
    Clin Cancer Res 13:994-9. 2007
    ..We sought to determine the effect of bTubIII on patient outcome and benefit from adjuvant chemotherapy in the JBR.10 trial...
  7. ncbi request reprint Induction chemoradiation and surgical resection for superior sulcus non-small-cell lung carcinomas: long-term results of Southwest Oncology Group Trial 9416 (Intergroup Trial 0160)
    Valerie W Rusch
    Thoracic Surgery Service, Memorial Sloan Kettering Cancer Center, New York, NY, USA
    J Clin Oncol 25:313-8. 2007
    ..On the basis of improved outcomes in other subsets of stage III NSCLC, this trial tested the feasibility of induction chemoradiotherapy for SS NSCLC...
  8. ncbi request reprint Validating the prognostic value of marker genes derived from a non-small cell lung cancer microarray study
    Fiona H Blackhall
    Division of Cellular and Molecular Biology, University Health Network, Ontario Cancer Institute, Princess Margaret Hospital and University of Toronto, Toronto, Ontario, Canada M5G 2M9
    Lung Cancer 46:197-204. 2004
    ....
  9. ncbi request reprint Skp2 gene copy number aberrations are common in non-small cell lung carcinoma, and its overexpression in tumors with ras mutation is a poor prognostic marker
    Chang Qi Zhu
    University Health Network, Ontario Cancer Institute and Princess Margaret Hospital, University of Toronto, Toronto, Ontario, Canada
    Clin Cancer Res 10:1984-91. 2004
    ..The Skp2 gene is located on a region of chromosome 5p that is commonly overrepresented in lung cancer. The present study aimed to evaluate Skp2 abnormalities and their prognostic value in non-small cell lung cancer (NSCLC)...
  10. ncbi request reprint Molecular profiling of non-small cell lung cancer and correlation with disease-free survival
    Dennis A Wigle
    Thoracic Oncology Site Group, Princess Margaret Hospital, Samuel Lunenfeld Research Institute of Mount Sinai Hospital, University of Toronto, 610 University Avenue, Toronto, Ontario, Canada M5G 2M9
    Cancer Res 62:3005-8. 2002
    ..The results provide evidence that molecular subtyping of NSCLC can identify distinct profiles of gene expression correlating with disease-free survival...
  11. ncbi request reprint Prognostic and predictive importance of p53 and RAS for adjuvant chemotherapy in non small-cell lung cancer
    Ming Sound Tsao
    Department of Hematology and Oncology, Princess Margaret Hospital, 610 University Avenue, Toronto, Ontario M5G 2M9, Canada
    J Clin Oncol 25:5240-7. 2007
    ....